METTL3/YTHDF1 stabilizes CORO6 expression promoting osteosarcoma progression through glycolysis

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Osteosarcoma is a prevalent bone cancer in young individuals, marked by aggressive growth and metastasis.
• Coronin 6 (CORO6), a protein regulating actin dynamics, has an uncharacterized role in osteosarcoma.
• Understanding CORO6's function is crucial for developing novel osteosarcoma treatments.

Purpose of the Study:

• To investigate the role of Coronin 6 (CORO6) in osteosarcoma development and progression.
• To elucidate the molecular mechanisms by which CORO6 influences osteosarcoma cell behavior.
• To evaluate CORO6 as a potential therapeutic target and prognostic biomarker for osteosarcoma.

Main Methods:

• Quantitative analysis of CORO6 expression in osteosarcoma patient samples.
• In vitro studies involving knockdown of CORO6 to assess effects on cell proliferation, migration, and invasion.
• In vivo xenograft models to evaluate CORO6's impact on tumor growth.
• Investigation of CORO6's interaction with the Wnt/β-catenin signaling pathway and its role in glycolysis.
• Analysis of m6A modification of CORO6 mRNA mediated by METTL3/YTHDF1.

Main Results:

• CORO6 expression is significantly upregulated in osteosarcoma tissues.
• Reduced CORO6 levels markedly inhibit osteosarcoma cell proliferation, migration, and invasion.
• CORO6 deficiency effectively suppresses osteosarcoma growth in vivo.
• CORO6 activates the Wnt/β-catenin pathway and promotes glycolysis in osteosarcoma cells.
• METTL3/YTHDF1-induced m6A modification enhances CORO6 mRNA stability and expression.

Conclusions:

• CORO6 functions as an oncogene in osteosarcoma, driving tumor progression.
• CORO6 represents a promising prognostic biomarker and therapeutic target for osteosarcoma.
• Targeting CORO6 may offer a novel strategy for osteosarcoma treatment.